Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.

Iihara H, Shimokawa M, Hayashi T, Kawazoe H, Saeki T, Aiba K, Tamura K.

Oncologist. 2019 Oct 21. pii: theoncologist.2019-0292. doi: 10.1634/theoncologist.2019-0292. [Epub ahead of print]

PMID:
31636146
2.

Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan.

Matsumoto H, Shimokawa M, Nasu K, Shikama A, Shiozaki T, Futagami M, Kai K, Nagano H, Mori T, Yano M, Sugino N, Fujimoto E, Yoshioka N, Nakagawa S, Shimada M, Tokunaga H, Yamada Y, Tsuruta T, Tasaki K, Nishikawa R, Kuji S, Motohashi T, Ito K, Yamada T, Teramoto N.

J Gynecol Oncol. 2019 Nov;30(6):e103. doi: 10.3802/jgo.2019.30.e103.

3.

Risk factors for the metabolic syndrome components of hypertension, diabetes mellitus, and dyslipidemia after living donor liver transplantation.

Toshima T, Yoshizumi T, Inokuchi S, Kosai-Fujimoto Y, Kurihara T, Yoshiya S, Mano Y, Takeishi K, Itoh S, Harada N, Ikegami T, Soejima Y, Shimokawa M, Maehara Y, Mori M.

HPB (Oxford). 2019 Sep 24. pii: S1365-182X(19)30695-1. doi: 10.1016/j.hpb.2019.08.008. [Epub ahead of print]

PMID:
31561946
4.

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer.

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T.

Ann Oncol. 2019 Sep 25. pii: mdz399. doi: 10.1093/annonc/mdz399. [Epub ahead of print]

PMID:
31553438
5.

18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer.

Takada K, Toyokawa G, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Haro A, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M.

Sci Rep. 2019 Sep 16;9(1):13362. doi: 10.1038/s41598-019-50079-2.

6.

Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study.

Naito Y, Kai Y, Ishikawa T, Fujita T, Uehara K, Doihara H, Tokunaga S, Shimokawa M, Ito Y, Saeki T.

Breast Cancer. 2019 Aug 12. doi: 10.1007/s12282-019-01001-1. [Epub ahead of print]

PMID:
31407150
7.

Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection.

Itoh S, Yugawa K, Shimokawa M, Yoshiya S, Mano Y, Takeishi K, Toshima T, Maehara Y, Mori M, Yoshizumi T.

BJS Open. 2019 Apr 29;3(4):500-508. doi: 10.1002/bjs5.50170. eCollection 2019 Aug.

8.

Characterization of human pegivirus infection in liver transplantation recipients.

Izumi T, Sakata K, Okuzaki D, Inokuchi S, Tamura T, Motooka D, Nakamura S, Ono C, Shimokawa M, Matsuura Y, Mori M, Fukuhara T, Yoshizumi T.

J Med Virol. 2019 Dec;91(12):2093-2100. doi: 10.1002/jmv.25555. Epub 2019 Aug 4.

PMID:
31350911
9.

Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

Haratake N, Seto T, Takamori S, Toyozawa R, Nosaki K, Miura N, Ohba T, Toyokawa G, Taguchi K, Yamaguchi M, Shimokawa M, Takenoyama M.

Thorac Cancer. 2019 Sep;10(9):1779-1787. doi: 10.1111/1759-7714.13143. Epub 2019 Jul 23.

10.

Perioperative Allogeneic Blood Transfusion Does not Influence Patient Survival After Hepatectomy for Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Yamashita YI, Hayashi H, Imai K, Okabe H, Nakagawa S, Kitamura F, Uemura N, Nakao Y, Yusa T, Itoyama R, Yamao T, Umesaki N, Miyata T, Chikamoto A, Shimokawa M, Baba H.

World J Surg. 2019 Nov;43(11):2894-2901. doi: 10.1007/s00268-019-05085-w.

PMID:
31312946
11.

Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan.

Yoshida I, Tamura K, Miyamoto T, Shimokawa M, Takamatsu Y, Nanya Y, Matsumura I, Gotoh M, Igarashi T, Takahashi T, Aiba K, Kumagai K, Ishizawa K, Kurita N, Usui N, Hatake K.

In Vivo. 2019 Jul-Aug;33(4):1355-1362. doi: 10.21873/invivo.11611.

12.

Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.

Iihara H, Shimokawa M, Gomyo T, Fujita Y, Yoshida T, Funaguchi N, Minato K, Kaito D, Osawa T, Yamada M, Hirose C, Suzuki A, Ohno Y.

BMJ Open. 2019 Jul 4;9(7):e028056. doi: 10.1136/bmjopen-2018-028056.

13.

Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.

Kurozumi A, Okada Y, Shimokawa M, Goshima Y, Otsuka T, Narisawa M, Torimoto K, Tanaka Y.

Diabetes Technol Ther. 2019 Jul;21(7):385-392. doi: 10.1089/dia.2019.0099. Epub 2019 Jun 17.

PMID:
31210529
14.

The Role of DNA Repair Glycosylase OGG1 in Intrahepatic Cholangiocarcinoma.

Sakata K, Yoshizumi T, Izumi T, Shimokawa M, Itoh S, Ikegami T, Harada N, Toshima T, Mano Y, Mori M.

Anticancer Res. 2019 Jun;39(6):3241-3248. doi: 10.21873/anticanres.13465.

PMID:
31177174
15.

Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.

Takada K, Shimokawa M, Tanaka K, Kohashi K, Haro A, Osoegawa A, Tagawa T, Azuma K, Okamoto I, Oda Y, Mori M.

PLoS One. 2019 Jun 4;14(6):e0217991. doi: 10.1371/journal.pone.0217991. eCollection 2019.

16.

Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).

Suzuki N, Hazama S, Nagasaka T, Tanioka H, Iwamoto Y, Negoro Y, Yamauchi M, Kobayashi M, Okuda H, Fujishima N, Nishimura T, Yamanaka N, Toyota K, Mori Y, Nakagami Y, Shimokawa M, Nagano H, Okajima M.

Int J Clin Oncol. 2019 Oct;24(10):1223-1230. doi: 10.1007/s10147-019-01473-3. Epub 2019 May 29.

17.

The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer.

Shimamatsu S, Takenoyama M, Shimokawa M, Takada K, Edagawa M, Toyozawa R, Nosaki K, Oba T, Tagawa T, Yamaguchi M, Taguchi K, Seto T.

Ann Thorac Surg. 2019 Oct;108(4):1080-1086. doi: 10.1016/j.athoracsur.2019.04.026. Epub 2019 May 16.

PMID:
31103386
18.

Clinical and Prognostic Significance of the Epithelial-Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score-Matched Analysis.

Matsubara T, Tagawa T, Takada K, Toyokawa G, Shimokawa M, Kozuma Y, Akamine T, Haro A, Osoegawa A, Mori M.

Clin Lung Cancer. 2019 Jul;20(4):e504-e513. doi: 10.1016/j.cllc.2019.04.006. Epub 2019 Apr 19.

PMID:
31103348
19.

The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.

Matsubara T, Toyokawa G, Takada K, Kinoshita F, Kozuma Y, Akamine T, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Mori M.

PLoS One. 2019 May 1;14(5):e0215103. doi: 10.1371/journal.pone.0215103. eCollection 2019.

20.

A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Tagawa T, Oda Y, Maehara Y.

J Thorac Dis. 2019 Mar;11(3):927-935. doi: 10.21037/jtd.2019.01.76.

21.

Significance of the Red Blood Cell Distribution Width in Resected Pathologic Stage I Nonsmall Cell Lung Cancer.

Toyokawa G, Shoji F, Yamazaki K, Shimokawa M, Takeo S.

Semin Thorac Cardiovasc Surg. 2019 Apr 19. pii: S1043-0679(19)30134-0. doi: 10.1053/j.semtcvs.2019.04.011. [Epub ahead of print]

PMID:
31009697
22.

Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.

Takada K, Shimokawa M, Akamine T, Ono Y, Haro A, Osoegawa A, Tagawa T, Mori M.

Anticancer Res. 2019 Apr;39(4):1987-1996. doi: 10.21873/anticanres.13309.

PMID:
30952742
23.

Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy.

Uchida M, Nakamura T, Shima T, Mori Y, Yoshimoto G, Kato K, Shimokawa M, Hosohata K, Miyamoto T, Akashi K.

Pharmazie. 2019 Apr 1;74(4):250-254. doi: 10.1691/ph.2019.8889.

PMID:
30940311
24.

High filamin-C expression predicts enhanced invasiveness and poor outcome in glioblastoma multiforme.

Kamil M, Shinsato Y, Higa N, Hirano T, Idogawa M, Takajo T, Minami K, Shimokawa M, Yamamoto M, Kawahara K, Yonezawa H, Hirano H, Furukawa T, Yoshimoto K, Arita K.

Br J Cancer. 2019 Apr;120(8):819-826. doi: 10.1038/s41416-019-0413-x. Epub 2019 Mar 14.

25.

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.

Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1916-1924. doi: 10.1245/s10434-019-07231-z. Epub 2019 Feb 27.

PMID:
30815801
26.

Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.

Iihara H, Shimokawa M, Abe M, Hayasaki Y, Fujita Y, Nagasawa Y, Sakurai M, Matsuoka R, Suzuki A, Morishige K.

BMJ Open. 2019 Jan 17;9(1):e024357. doi: 10.1136/bmjopen-2018-024357.

27.

Emergence of Wrinkles during the Curing of Coatings.

Shimokawa M, Yoshida H, Komatsu T, Omachi R, Kudo K.

Gels. 2018 May 3;4(2). pii: E41. doi: 10.3390/gels4020041.

28.

Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.

Takada K, Kohashi K, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Seto T, Oda Y, Maehara Y.

Lung Cancer. 2019 Feb;128:26-32. doi: 10.1016/j.lungcan.2018.12.008. Epub 2018 Dec 10.

PMID:
30642449
29.

The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: a comparison with smokers.

Akamine T, Tagawa T, Shimokawa M, Matsubara T, Kozuma Y, Haratake N, Takamori S, Toyokawa G, Maehara Y.

Interact Cardiovasc Thorac Surg. 2019 May 1;28(5):735-743. doi: 10.1093/icvts/ivy329.

PMID:
30602039
30.

Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy.

Shimokawa M, Hayashi T, Kogawa T, Matsui R, Mizuno M, Kikkawa F, Saeki T, Aiba K, Tamura K.

Anticancer Res. 2019 Jan;39(1):225-230. doi: 10.21873/anticanres.13101.

PMID:
30591462
31.

PCR Analysis Methods for Detection and Identification of Beer-Spoilage Lactic Acid Bacteria.

Asano S, Shimokawa M, Suzuki K.

Methods Mol Biol. 2019;1887:95-107. doi: 10.1007/978-1-4939-8907-2_9.

PMID:
30506252
32.

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).

Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).

Eur J Cancer. 2018 Dec;105:41-49. doi: 10.1016/j.ejca.2018.09.024. Epub 2018 Nov 2.

PMID:
30391779
33.

A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.

Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, Oda Y, Maehara Y.

Ann Thorac Surg. 2019 Feb;107(2):393-400. doi: 10.1016/j.athoracsur.2018.08.056. Epub 2018 Oct 18.

PMID:
30343006
34.

Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study.

Hayashi T, Shimokawa M, Matsuo K, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, Hanada K, Tsumagari K, Okubo N, Koutake Y, Sakata K, Kawamata Y, Goto T, Tsurusaki Y, Koyabu M.

Cancer Manag Res. 2018 Oct 4;10:4249-4255. doi: 10.2147/CMAR.S176574. eCollection 2018.

35.

Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial.

Oki E, Shimokawa M, Ando K, Murata A, Takahashi T, Maeda K, Kusumoto T, Munemoto Y, Nakanishi R, Nakashima Y, Saeki H, Maehara Y.

Surgery. 2019 Mar;165(3):586-592. doi: 10.1016/j.surg.2018.08.027. Epub 2018 Oct 9.

PMID:
30314724
36.

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.

Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5897-5901. doi: 10.21873/anticanres.12933.

PMID:
30275216
37.

A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.

Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tsukamoto S, Hamatake M, Yokoyama H, Ueda H, Motohiro A, Tagawa T, Shoji F, Kometani T, Saito G, Fukuyama Y, Toyokawa G, Osoegawa A, Emi Y, Maehara Y; Kyushu University Lung Surgery Study Group (KLSS) Japan.

Lung Cancer. 2018 Oct;124:255-259. doi: 10.1016/j.lungcan.2018.08.015. Epub 2018 Aug 19.

PMID:
30268470
38.

Power law observed in the motion of an asymmetric camphor boat under viscous conditions.

Shimokawa M, Oho M, Tokuda K, Kitahata H.

Phys Rev E. 2018 Aug;98(2-1):022606. doi: 10.1103/PhysRevE.98.022606.

PMID:
30253558
39.

Feasibility of All-in-One Venoplasty With a Venous Cuff Using an Opened Round Ligament for the Right Lobe Graft in Living Donor Liver Transplantation.

Toshima T, Yoshizumi T, Shimokawa M, Ikegami T, Harada N, Itoh S, Mano Y, Motomura T, Soejima Y, Maehara Y.

Liver Transpl. 2019 Jan;25(1):171-175. doi: 10.1002/lt.25339. No abstract available.

PMID:
30230163
40.
41.

Radiological Features of IDO1+/PDL1+ Lung Adenocarcinoma: A Retrospective Single-institution Study.

Takada K, Toyokawa G, Tagawa T, Shimokawa M, Kohashi K, Haro A, Osoegawa A, Oda Y, Maehara Y.

Anticancer Res. 2018 Sep;38(9):5295-5303. doi: 10.21873/anticanres.12856.

PMID:
30194181
42.

Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer.

Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL.

Oncotarget. 2018 Aug 17;9(64):32321-32330. doi: 10.18632/oncotarget.25962. eCollection 2018 Aug 17.

43.

Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis.

Nanki K, Toshimitsu K, Takano A, Fujii M, Shimokawa M, Ohta Y, Matano M, Seino T, Nishikori S, Ishikawa K, Kawasaki K, Togasaki K, Takahashi S, Sukawa Y, Ishida H, Sugimoto S, Kawakubo H, Kim J, Kitagawa Y, Sekine S, Koo BK, Kanai T, Sato T.

Cell. 2018 Aug 9;174(4):856-869.e17. doi: 10.1016/j.cell.2018.07.027.

44.

A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.

Nishio S, Shimokawa M, Tasaki K, Nasu H, Yoshimitsu T, Matsukuma K, Terada A, Tsuda N, Kawano K, Ushijima K.

Gynecol Oncol. 2018 Sep;150(3):432-437. doi: 10.1016/j.ygyno.2018.07.014. Epub 2018 Jul 21.

PMID:
30037491
45.

Benefits of laparoscopic surgery compared to open standard surgery for gastric carcinoma in elderly patients: propensity score-matching analysis.

Yamamoto M, Shimokawa M, Kawano H, Ohta M, Yoshida D, Minami K, Ikebe M, Morita M, Toh Y.

Surg Endosc. 2019 Feb;33(2):510-519. doi: 10.1007/s00464-018-6325-7. Epub 2018 Jul 20.

PMID:
30030615
46.

Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).

Nishio S, Aihara S, Shimokawa M, Fujishita A, Taniguchi S, Hachisuga T, Yanazume S, Kobayashi H, Murakami F, Numa F, Kotera K, Okura N, Toki N, Yokoyama M, Ushijima K.

J Gynecol Oncol. 2018 Sep;29(5):e77. doi: 10.3802/jgo.2018.29.e77. Epub 2018 May 15.

47.

Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.

Kozuma Y, Takada K, Toyokawa G, Kohashi K, Shimokawa M, Hirai F, Tagawa T, Okamoto T, Oda Y, Maehara Y.

Eur J Cancer. 2018 Sep;101:20-29. doi: 10.1016/j.ejca.2018.06.020. Epub 2018 Jul 13.

PMID:
30014971
48.

Computed tomography features of resected lung adenocarcinomas with spread through air spaces.

Toyokawa G, Yamada Y, Tagawa T, Kamitani T, Yamasaki Y, Shimokawa M, Oda Y, Maehara Y.

J Thorac Cardiovasc Surg. 2018 Oct;156(4):1670-1676.e4. doi: 10.1016/j.jtcvs.2018.04.126. Epub 2018 Jun 6.

PMID:
29961590
49.

Impact of Preoperative Ultrasonography Screening for Carotid Artery Stenosis in Lung Cancer Patients.

Shoji F, Takeo S, Yamazaki K, Miura N, Katsura M, Oku Y, Shimokawa M.

Ann Thorac Surg. 2018 Oct;106(4):1047-1054. doi: 10.1016/j.athoracsur.2018.04.072. Epub 2018 May 28.

PMID:
29852144
50.

Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Honda H, Maehara Y.

Anticancer Res. 2018 Jun;38(6):3731-3734. doi: 10.21873/anticanres.12653.

PMID:
29848735

Supplemental Content

Loading ...
Support Center